DAAs Are Known to Be Effective with HCV. Why Aren’t They Used More?
Author: Margaret R. Moreland, J.D., M.L.S.
Source: Volume 20, Number 01, November/December 2018 , pp.15-16(2)
< previous article |next article > |return to table of contents
Abstract:
Direct-Acting Antivirals (DAAs) have been proved to achieve a 95% cure rate for hepatitis C infection with few side effects; they should be universally available and used in prisons and jails, where high rates of HCV pose a significant public health problem, yet their use is restricted. The authors of a new study in The Journal of Viral Hepatology, “Understanding Facilitators and Barriers of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection in Prison,” by Lise Lafferty, Jake Rance, Jason Grebely, Andrew R. Lloyd, Gregory J. Dore, and Carla Treloar, on behalf of the SToP-C Study Group, identify factors that limit the use of DAAs and suggest ways to increase their use.Keywords: Direct-Acting Antivirals; Hepatitis C Infection
Affiliations:
1: Contributing Editor.